ADMA Biologics, Inc.
Financials
Valuation Metrics
ADMA Biologics, Inc.'s Market Cap is $2.02B. At end of 2025 it was $4.34B. Ranked #2047 of 3,112 in US market (top 66%), #783 of 1,445 on NASDAQ (top 54%), #133 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.02B | US#2,047/3,112 Sec#133/269 |
| Revenue | $510M | US#2,335/3,112 Sec#81/269 |
| Net Income | $165M | US#1,357/3,112 Sec#47/269 |
| Total Assets | $665M | US#2,629/3,112 Sec#129/269 |
| Net Assets | $390M | US#2,420/3,112 Sec#138/269 |
| Employees | 640 | US#1,328/3,112 Sec#44/269 |
| Value | ||
| P/E | 12.24x | US#428/3,112 Sec#19/269 |
| P/B | 5.19x | US#2,206/3,112 Sec#145/269 |
| PEG | 0.18x | US#283/3,112 Sec#13/269 |
| P/S | 3.97x | US#2,065/3,112 Sec#61/269 |
| EV/EBITDA | 9.44x | US#670/3,112 Sec#25/269 |
| FCF Yield | 5.33% | US#1,217/3,112 Sec#44/269 |
| Profitability | ||
| ROE | 42.36% | US#153/3,112 Sec#15/269 |
| ROA | 24.86% | US#44/3,112 Sec#10/269 |
| Op. Margin | 40.57% | US#222/3,112 Sec#13/269 |
| Revenue Growth | -0.27% | US#2,262/3,112 Sec#126/269 |
| Earnings Growth | 68.48% | US#458/3,112 Sec#20/269 |
| Financial Health | ||
| Debt Ratio | 70.42% | US#787/3,112 Sec#155/269 |
| Total Debt | $204M | US#2,182/3,112 Sec#93/269 |
| FCF | $108M | US#1,636/3,112 Sec#59/269 |
| Cash | $138M | US#1,994/3,112 Sec#151/269 |
| Current Ratio | 6.95x | US#345/3,112 Sec#113/269 |
| Net Debt/EBITDA | 0.30x | US#750/3,112 Sec#42/269 |
| Performance | ||
| 1Y Return | -54.81% | US#3,019/3,112 Sec#254/269 |
| 1M Return | -2.40% | US#1,958/3,112 Sec#100/269 |
| From 52W High | -57.31% | US#2,901/3,112 Sec#235/269 |
| 1Y MDD | -65.25% | US#2,838/3,112 Sec#235/269 |
| Trading | ||
| Volume | 2,140,010 shares | US#846/3,112 Sec#75/269 |
| Trading Value | $19M | US#2,004/3,112 Sec#152/269 |
| Per Share | ||
| EPS | $0.62 | US#1,782/3,112 Sec#60/269 |
| BPS | $2.01 | US#2,504/3,112 Sec#176/269 |
Company Info
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.